Galatea Bio’s $25M Funding Boost for Global Biobank and AI-Driven Genomic Research
Galatea Bio secured $25 million in funding to build the Galatea Global Biobank1.
The biobank aims to include whole genome and exome sequencing data from 10 million participants worldwide, focusing on non-European ancestries12.
Founded in 2021 by Carlos D. Bustamante, Galatea Bio is addressing the lack of diversity in genomic datasets14.
The company utilizes AI-enhanced ancestry inference to develop proprietary polygenic risk scores and improve disease modeling1.
Galatea Bio operates a CAP-accredited biobank and clinical genetic testing laboratory1.
The funding will support the expansion of high-throughput sequencing, AI-powered genomic analysis, and industry partnerships1.
Galatea's approach aims to accelerate biomarker and drug discovery, enhance clinical diagnostics, and support biopharma partnerships5.
The company has strategic partnerships with institutions like Stanford University and the Chan-Zuckerberg Initiative12.
Galatea Bio's proprietary platforms, Galaxy-bio™ and Gnomix AI™, enhance ancestry-aware polygenic risk scoring and disease prediction models1.
The biobank is expected to reach 10 million data points by 2026, making it one of the most diverse biobanks in the world4.
Sources:
1. https://www.globenewswire.com/news-release/2025/03/27/3050467/0/en/Galatea-Bio-Secures-25M-to-Develop-Global-Biobank-and-Enable-Precision-Health-at-Scale-for-All.html
2. https://www.genomeweb.com/sequencing/genomic-data-analytics-firm-galatea-bio-raises-25m
4. https://www.illumina.com/company/news-center/feature-articles/biobank-for-the-americas-and-galatea-bio.html
5. https://www.finsmes.com/2025/03/galatea-bio-raises-25m-in-funding.html